A pyrrolesulfonamide derivative having the following formula (I): ##STR00001## wherein the ring P represented by ##STR00002## is a pyrrole ring having the following structure: ##STR00003## wherein R represents alkyl, cycloalkyl, cycloalkyl-alkyl or aralkyl; the dashed line indicates the presence or absence of a bond; and, when the bond is present, Z.sub.2 is not present and Z.sub.1 represents H but, when the bond is absent, Z.sub.1 represents H and Z.sub.2 represents OH or Z.sub.1 and Z.sub.2 are combined together to represent O or a group NOR.sub.1, in which R.sub.1 represents H, or alkyl, aralkyl or aryl; l stands for 0 or 1; A represents alkylene, alkenylene or alkynylene; and Y represents a group ##STR00004## in which W represents CH, C.dbd. or N; m stands for 0 or 1 when W is CH or N, or m stands for 1 when W is C.dbd.; B represents a specific divalent group; E.sub.1 and E.sub.2 each independently represents H or lower alkyl; and D represents an aromatic hydrocarbon group or heterocyclic group. The compound (I) has strong serotonin-2 receptor antagonistic action and low toxicity and less side effects, and is useful as a therapeutic for circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturbances.